Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-05-29
2007-05-29
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S136100, C424S178100
Reexamination Certificate
active
10774076
ABSTRACT:
The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.
REFERENCES:
patent: 4668629 (1987-05-01), Kaplan et al.
patent: 5115096 (1992-05-01), Shoyab et al.
patent: 5262298 (1993-11-01), Shipley et al.
patent: 5830995 (1998-11-01), Shoyab et al.
patent: 5855885 (1999-01-01), Smith et al.
patent: 6204359 (2001-03-01), Delaey et al.
patent: 6677436 (2004-01-01), Sato et al.
patent: 2002/0156263 (2002-10-01), Chen
patent: 1 074 617 (2001-02-01), None
patent: 1 249 237 (2002-10-01), None
patent: WO-90/14069 (1990-11-01), None
patent: WO-96/12019 (1996-04-01), None
patent: WO-97/23507 (1997-07-01), None
patent: WO-99/38972 (1999-08-01), None
patent: WO-01/70979 (2001-09-01), None
patent: WO-01/70984 (2001-09-01), None
patent: WO-01/96389 (2001-12-01), None
patent: WO-02/10449 (2002-02-01), None
patent: WO-02/41763 (2002-05-01), None
patent: WO -02/057414 (2002-07-01), None
patent: WO-02/074979 (2002-09-01), None
patent: WO-02/077234 (2002-10-01), None
patent: WO-02/085298 (2002-10-01), None
patent: WO-02/092000 (2002-11-01), None
patent: WO-03/008583 (2003-01-01), None
patent: WO-03/014159 (2003-02-01), None
patent: WO-03/022222 (2003-03-01), None
Rudikoff et al., Proc Natl Acad Sci., USA 1982, vol. 79, pp. 1979-1983.
Janeway, immunobiology, 6thEd. 2004, Garland Sciences, p. 110-112.
Communication Relating to the Results of the Partial International Search in PCT/US2004/004176.
Cook et al., “A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin,” Mol. Cell. Biol., 11, 2547-2557 (1991).
Cook et al., “Inhibition of autonomous human keratinocyte proliferation and amphiregulin mitogenic activity by sulfated polysaccharides,” In Vitro Cell. Dev. Biol. 28A, 218-222 (1992).
Cook, et al., “Amphiregulin Messenger RNA Is Elevated in Psoriatic Epidermis and Gastrointestinal Carcinomas,” Cancer Res. 52: 3224-3227 (1992).
Cook, et al., “Transgenic Expression of the Human Amphiregulin Gene Induces a Psoriasis-like Phenotype,” J. Clin. Invest. 100: 2286-2294 (1997).
Damstrup, et al., “Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis,” British Journal of Cancer 80(7): 1012-19 (Jun. 1999).
Johnson, G. R., et al., “Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells,” J. Biol. Chem. 268: 2924-2931 (1993).
Piepkorn et al., “Amphiregulin-dependent proliferation of cultured human keratinocytes: autocrine growth, the effects of exogenous recombinant cytokine, and apparent requirement for heparin-like glycosaminoglycans,” J. Cell. Physiol. 159, 114-120 (1994).
Piepkorn, et al., “Autocrine Regulation of Keratinocytes: the Emerging Role of Heparin-Binding, Epidermal Growth Factor-Related Growth Factors,” J. Invest. Dermatol. 111(5):715-721 (Nov. 1998).
Piepkorn, et al., “Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases,” Am. J. Dermatol. 18: 165-171 (1996).
Plowman et al., “The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity,” Mol. Cell. Biol. 10, 1969-1981 (1990).
Shoyab et al., “Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7,” Proc. Natl. Acad. Sci. USA 85, 6528-6532 (1988).
Shoyab et al., “Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor Family,” Science 243, 1074-1076 (1989).
Thompson, S.A., et al., “COOH-terminal extended recombinant amphiregulin with bioactivity comparable with naturally derived growth factor,” J. Biol. Chem. 271(30): 17927-31 (1996).
Cook et al., “Overexpression of Amphiregulin in the Epidermis of Transgenic Mice Induces a Psoriasis-Like Cutaneous Phenotype,” J. Invest. Dermatol. 113(5): 860 (Nov. 1999).
Hinton Paul R.
Kumar Shankar
Landolfi Nicholas F.
Tsurushita Naoya
Biro Michael
Chan Christina
Harlocker Susan
Kim Yunsoo
PDL Biopharma, Inc
LandOfFree
Amphiregulin antibodies and their use to treat cancer and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amphiregulin antibodies and their use to treat cancer and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amphiregulin antibodies and their use to treat cancer and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3772048